Last reviewed · How we verify

Prilocaine Hydrochloride 2% Injection

Assiut University · FDA-approved active Small molecule Quality 5/100

Prilocaine Hydrochloride 2% Injection is a Small molecule drug developed by Assiut University. It is currently FDA-approved. Also known as: Takipril.

At a glance

Generic namePrilocaine Hydrochloride 2% Injection
Also known asTakipril
SponsorAssiut University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prilocaine Hydrochloride 2% Injection

What is Prilocaine Hydrochloride 2% Injection?

Prilocaine Hydrochloride 2% Injection is a Small molecule drug developed by Assiut University.

Who makes Prilocaine Hydrochloride 2% Injection?

Prilocaine Hydrochloride 2% Injection is developed and marketed by Assiut University (see full Assiut University pipeline at /company/assiut-university).

Is Prilocaine Hydrochloride 2% Injection also known as anything else?

Prilocaine Hydrochloride 2% Injection is also known as Takipril.

What development phase is Prilocaine Hydrochloride 2% Injection in?

Prilocaine Hydrochloride 2% Injection is FDA-approved (marketed).

Related